ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
leveller
|
47 |
8.8K |
2 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
47
|
8.8K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
leveller
|
47 |
8.8K |
11 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
47
|
8.8K
|
11
|
|
ASX - By Stock
|
BMR |
Re:
Ann: Dittmer Stage 4 Drilling Delivers 193 g/t Au Intersection
|
|
leveller
|
9 |
1.9K |
3 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
9
|
1.9K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Entitlement Offer - Offer Booklet
|
|
leveller
|
7 |
1.8K |
0 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
7
|
1.8K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Entitlement Offer - Offer Booklet
|
|
leveller
|
7 |
1.8K |
0 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
7
|
1.8K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Entitlement Offer - Offer Booklet
|
|
leveller
|
7 |
1.8K |
0 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
7
|
1.8K
|
0
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Cyclopharm Business Update
|
|
leveller
|
5 |
1.3K |
0 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
5
|
1.3K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Entitlement Offer - Offer Booklet
|
|
leveller
|
7 |
1.8K |
1 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
7
|
1.8K
|
1
|
|
ASX - By Stock
|
SMN |
Re:
FAA
|
|
leveller
|
3 |
820 |
2 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
3
|
820
|
2
|
|
ASX - By Stock
|
BMR |
Re:
Ann: Investor Presentation April 2024
|
|
leveller
|
2 |
920 |
0 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
2
|
920
|
0
|
|
ASX - By Stock
|
MVP |
Re:
Ann: Quarterly Report Webcast Details 3Q24
|
|
leveller
|
29 |
8.9K |
3 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
29
|
8.9K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
New email reg. JC
|
|
leveller
|
12 |
3.4K |
7 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
12
|
3.4K
|
7
|
|
ASX - By Stock
|
IG6 |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
leveller
|
10 |
2.2K |
1 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
10
|
2.2K
|
1
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Becoming a substantial holder
|
|
leveller
|
13 |
3.0K |
1 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
13
|
3.0K
|
1
|
|
ASX - By Stock
|
MVP |
Re:
Ann: Quarterly Report Webcast Details 3Q24
|
|
leveller
|
29 |
8.9K |
4 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
29
|
8.9K
|
4
|
|
ASX - By Stock
|
SMN |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
leveller
|
45 |
8.6K |
10 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
45
|
8.6K
|
10
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Trading Halt
|
|
leveller
|
21 |
6.5K |
1 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
21
|
6.5K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Trading Halt
|
|
leveller
|
21 |
6.5K |
2 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
21
|
6.5K
|
2
|
|
ASX - By Stock
|
BMR |
Re:
Ann: Dittmer Drilling Doubles Area of Known Mineralisation
|
|
leveller
|
2 |
786 |
3 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
2
|
786
|
3
|
|
ASX - By Stock
|
MVP |
Re:
Ann: Change of Director's Interest Notice
|
|
leveller
|
6 |
2.9K |
4 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
6
|
2.9K
|
4
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Trading Halt
|
|
leveller
|
21 |
6.5K |
5 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
21
|
6.5K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
leveller
|
44 |
11K |
2 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
44
|
11K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
leveller
|
44 |
11K |
0 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
44
|
11K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
leveller
|
44 |
11K |
0 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
44
|
11K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
leveller
|
44 |
11K |
0 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
44
|
11K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
leveller
|
44 |
11K |
0 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
44
|
11K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
leveller
|
44 |
11K |
4 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
44
|
11K
|
4
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
leveller
|
44 |
11K |
0 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
44
|
11K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
leveller
|
58 |
14K |
0 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
58
|
14K
|
0
|
|
ASX - By Stock
|
MVP |
Re:
Ann: Change in substantial holding
|
|
leveller
|
26 |
11K |
6 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
26
|
11K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Clinical milestones for 2024 & 2023 successes highlighted
|
|
leveller
|
26 |
9.2K |
4 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
26
|
9.2K
|
4
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
leveller
|
58 |
14K |
0 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
58
|
14K
|
0
|
|
ASX - By Stock
|
MVP |
Re:
Ann: Change in substantial holding
|
|
leveller
|
26 |
11K |
5 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
26
|
11K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Clinical milestones for 2024 & 2023 successes highlighted
|
|
leveller
|
26 |
9.2K |
7 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
26
|
9.2K
|
7
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
leveller
|
58 |
14K |
3 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
58
|
14K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Successfully Passes Efficacy Interim Analysis
|
|
leveller
|
279 |
86K |
3 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
279
|
86K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
leveller
|
43 |
18K |
4 |
10/03/24 |
10/03/24 |
ASX - By Stock
|
43
|
18K
|
4
|
|
ASX - By Stock
|
MVP |
Re:
Ann: 2024 Half Year Announcement
|
|
leveller
|
34 |
13K |
5 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
34
|
13K
|
5
|
|
ASX - By Stock
|
EYE |
Re:
Nova Eye Medical (EYE) Discussion
|
|
leveller
|
2.8K |
673K |
0 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
2.8K
|
673K
|
0
|
|
ASX - By Stock
|
EYE |
Re:
Nova Eye Medical (EYE) Discussion
|
|
leveller
|
2.8K |
673K |
7 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
2.8K
|
673K
|
7
|
|
ASX - By Stock
|
IG6 |
Re:
Ann: RIU Explorers Conference 2024 Presentation
|
|
leveller
|
11 |
5.1K |
1 |
24/02/24 |
24/02/24 |
ASX - By Stock
|
11
|
5.1K
|
1
|
|
ASX - By Stock
|
BMR |
Re:
Ann: Addendum to December 2023 Quarterly Activities Report
|
|
leveller
|
1 |
551 |
0 |
17/02/24 |
17/02/24 |
ASX - By Stock
|
1
|
551
|
0
|
|
ASX - By Stock
|
IG6 |
Re:
Ann: New micronising plant Commissioned in Collie
|
|
leveller
|
5 |
2.0K |
6 |
12/02/24 |
12/02/24 |
ASX - By Stock
|
5
|
2.0K
|
6
|
|
ASX - By Stock
|
CYC |
Re:
Ann: CYC and Yale Translational Research Partner on Technegas
|
|
leveller
|
1 |
532 |
0 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
1
|
532
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
|
|
leveller
|
21 |
7.3K |
3 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
21
|
7.3K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
|
|
leveller
|
21 |
7.3K |
4 |
18/01/24 |
18/01/24 |
ASX - By Stock
|
21
|
7.3K
|
4
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Pause in Trading
|
|
leveller
|
11 |
2.5K |
1 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
11
|
2.5K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
CHM Bell Potter booking building
|
|
leveller
|
24 |
5.0K |
3 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
24
|
5.0K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Pause in Trading
|
|
leveller
|
11 |
2.5K |
2 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
11
|
2.5K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
CHM Bell Potter booking building
|
|
leveller
|
24 |
5.0K |
2 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
24
|
5.0K
|
2
|
|